Drug Profile
Research programme: anti-cancer antibody - Chong Kun Dang Pharmaceutical
Alternative Names: CKD-10101Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Chong Kun Dang
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in South Korea (Parenteral)